Developer docs
API playgroundTry for free, no card

Search company profiles

Bota Biosciences

Full company profile

uuid0000sth

Namestring
Bota Biosciences
Legal namestring
Bota Biosciences
Websiteurl
bota.bio
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Bota Biosciences (恩和科技) is an industrial synthetic biology and Physical AI company founded in September 2019 by Dr. Cheryl Cui in Hangzhou, China. The company builds and operates the SAION AI Physical AI platform — a three-layer system integrating Cognition (multi-scale biological understanding via AI4Science models and proprietary Cell2Cloud datasets), Orchestration (an Agent Harness engine coordinating 316 specialized scientific tools), and Closed-loop Execution (BPL-driven automated wet-lab operation). This platform is anchored by the in-house Bota Biofoundry (Cell2Cloud) which has been operational since 2020, screening 1.5M+ strains per year across 48 bioreactors and generating a proprietary dataset of 10M+ multi-modal closed-loop data points and 1.8B+ process data points. Bota also developed and open-sourced the Biology Protocol Language (BPL) and BPL-COGEN compiler pipeline under MIT License, achieving 95.1% first-pass and 98.6% after two rounds of compiler-simulation on 300 Nature Protocols papers.

The company monetizes across three revenue streams: (1) B2B precision fermentation services and joint development with industrial partners (NHU, Puratos, BASF, Syensqo, Proya, Pechoin, Yili) using a land-and-expand model with multi-year strategic alliances; (2) self-developed branded bio-based product sales through two wholly-owned sub-brands — Yucca Elements for personal care (Prorylia® FN, Re² Coffea Arabica Peptide, ZeaVida) and HeliaGenesis for food/nutrition bio-preservatives (Purtect™ Nisin, Natamycin, ε-Poly-Lysine, Lysozyme); and (3) technology transfer, licensing and commercialization royalties. The company holds an integrated industrial footprint of 130,000 m² with 600+ tons/year capacity across Hangzhou (HQ + LEAP R&D Center), Shandong, and Ordos production sites, plus a US regional office in Lafayette, CA.

Bota was recognized as a World Economic Forum Technology Pioneers Unicorn (January 2024), selected for the WEF MINDS program (2026), named to Forbes China's AI Technology Enterprise Top 50 (2026), and designated one of Hangzhou's "New Eight Steeds" (2026). The company achieved FDA GRAS certification for ZeaVida® precision-fermented zeaxanthin in May 2026 — a world-first for cell-factory carotenoid production — and rebranded in March 2026 from 恩和生物 (Enhe Bio) to 恩和科技 (Enhe Technology) to reflect its AI-driven positioning. Disclosed revenue was approximately 100 million RMB by December 2023 (up from >10 million RMB in May 2022); cumulative disclosed funding exceeds US$100M+ across Series A (May 2020), Series B (July 2021) and Series B+ (June 2024), with investors including BASF Venture Capital, Sherpa Healthcare Partners, Matrix Partners China, Baidu Ventures, HSG, 5Y Capital, and Source Code Capital.

Short descriptiontext

Bota Biosciences (恩和科技) is a Hangzhou-based synthetic biology and Physical AI company that builds the SAION AI platform and Bota Biofoundry to design, engineer, and industrially produce precision-fermented bio-based ingredients for food, nutrition, personal care, and fine chemicals customers including BASF, Syensqo, NHU, Proya, and Puratos.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLafayette, United States
HQ citystring
Lafayette
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic biology, precision fermentation, bio-based ingredients, enzyme engineering, biomanufacturing services
Industry5 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYEUAAAIAL
Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYAFABAEAM
Biological Formulation, Fermentation & Scale-Up Manufacturing
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Industrial Synthetic Biology / Bio-manufacturing
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Precision fermentation services & joint development
TypeProfessional Services
Description

B2B service offering full-stack precision fermentation capabilities — partners bring market insight and target molecules; Bota delivers strain engineering, process development, scale-up, and industrialization. Land-and-expand model with multi-year strategic alliances (e.g., 5-year Syensqo partnership).

bota.bio
2Branded bio-based product sales (Yucca Elements / HeliaGenesis)
TypeHardware Sales
Description

Self-developed and mass-produced high-value bio-based ingredients for personal care (Yucca Elements: Prorylia FN, Re2 Coffea Arabica Peptide, ZeaVida precision-fermented zeaxanthin) and food/nutrition (HeliaGenesis: Purtect Nisin/Natamycin/ε-Poly-Lysine/Lysozyme). Distributed via own e-commerce storefronts and partner commercial networks.

bota.bio
3Technology transfer, licensing and commercialization royalties
TypeLicensing Royalties
Description

Out-licensing of proprietary strains, processes and platforms to industrial partners (e.g., NHU strain commercialization delivering multi-million RMB economic value; Puratos enzyme co-development). Includes long-tail royalty potential on commercialized outputs.

bota.bio
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Infrastructure, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Yucca Elements (青然新护)
Description

Wholly-owned personal care and beauty synthetic biology ingredients sub-brand specializing in pure, natural, high-efficiency bio-based raw materials such as Prorylia® FN Fibronectin and Re² Coffea Arabica peptides.

bota.bio
+1 more record
Core offering1 text field

Bota Biosciences operates an AI-driven industrial synthetic biotechnology platform that programs biological systems for precision fermentation and clean bio-manufacturing. Its core commercial offerings are B2B precision-fermentation services (strain engineering, process development, scale-up, industrialization) delivered to Fortune 500 customers, branded bio-based ingredients (bio-preservatives under HeliaGenesis, personal care proteins under Yucca Elements), and technology/strain licensing to industrial partners. The proprietary SAION AI Physical AI Platform and Bota Biofoundry (Cell2Cloud) compress the Design-Build-Test-Learn cycle and link in-silico design directly to industrial-scale fermentation production.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • R&D-to-industrialization cycle compressed from 3-5 years to as short as 6 months via SAION AI
+6 more records
Product and service3 records
1SAION AI Physical AI Platform
CategoryCore AI Platform
Description

End-to-end Physical AI platform that autonomously drives biological design from in-silico cognition through multi-agent orchestration to closed-loop wet-lab execution; offered to biomanufacturing enterprises and used internally to compress R&D-to-industrialization cycles from 3-5 years to as short as 6 months.

2Bota Biofoundry (Cell2Cloud Biofoundry)
CategoryBiofoundry / Automation Platform
Description

In-house full-stack biofoundry platform combining software algorithms, high-throughput data, deep learning, and biotechnology to accelerate Design-Build-Test-Learn cycles for industrial strain engineering, enzyme engineering, and protein discovery; offered to enterprise biomanufacturing customers.

3Bota Camino
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-17
Description

Disclosed in the Forbes China AI Tech Top 50 announcement as world-500/industry-leading deep partnerships spanning food, nutrition and personal care (also referenced across multiple press releases and on the company's "Proud Partnership with Industry Leaders" homepage section).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-21
Description

Strategic-level cooperation signing at Proya's Longwu R&D Center in Hangzhou — Proya's first strategic collaboration with a synthetic biology company. Focused on integrated application of synthetic biology and AI in cosmetics and biomedical aesthetics; co-developing AI-designed customized bioactive ingredients.

3Syensqo
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-02-10
Description

Five-year strategic partnership combining Bota's Performance Protein Platform with Syensqo's 40+ years of hair/scalp care expertise, supported by Syensqo's Renewable Materials and Biotechnology Platform and Syensqo Ventures. Expanded in March 2026 to globally distribute Re2 Coffea Arabica Peptide via Syensqo's commercial network.

bota.bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-14
Description

Joint collaboration to expand Puratos' natural enzyme portfolio for bakery, patisserie and chocolate using Bota's extensive enzyme sequence/structure database and Biofoundry platform. Bota identifies and engineers the natural enzymes; Puratos develops and applies them at commercial scale.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-23
Description

Strategic partnership leveraging NHU's specialty chemical production experience with Bota's full-stack strain development platform. First co-developed project successfully commercialized, generating tens of millions RMB in economic benefits with projected several hundred million RMB in total product value.

Strategic tierFlagshipTypeOthersAnnounced on2024-01-31
Description

Selected to the WEF Unicorns list (alongside OpenAI, Pivot Bio, Asimov) and invited to speak on the 'Bio-based Path to Net Zero' panel at Davos 2024 — a non-commercial recognition of Bota's leadership, impact, and innovation in industrial biotechnology.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-09-07
Description

Deepened strategic cooperation building on a relationship since 2019. Bota's analytical platform is equipped with Agilent UHPLC, GC, LC-MS/MS, GC-MS and RapidFire high-throughput LC-MS systems; both parties will share technology and industrial resources to optimize metabolic flow analysis, protein quantification, and fermentation online detection for synthetic biology applications.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a proud industry-leader partner on Bota's homepage (Galactic is a lactic acid / natural preservatives specialist), suggesting a supply, development or distribution relationship in the bio-preservative value chain.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a proud industry-leader partner on Bota's homepage — partnership in the personal care / consumer products value chain.

10Wahaha (娃哈哈), Yurun (雨润), Jinluo (金锣), Beter and other Chinese food brands
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Disclosed on Bota's Chinese homepage as partner customers for food/nutrition ingredients (bio-preservatives and functional ingredients). Customer-type relationships rather than equity alliances.

bota.bio
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Conagen is a precision fermentation company developing bio-based ingredients for food, flavor, fragrance, and personal care — a direct competitor to Bota in fermentation-based bio-preservatives and performance proteins for personal care.

TypeBroad incumbent
Description

Corbion is a global leader in lactic acid, bio-preservatives (similar to Bota's Nisin/Natamycin/ε-Poly-Lysine portfolio), and natural food ingredients — a directly overlapping product portfolio in bio-preservation.

3Culture Biosciences
TypeEmerging player
Description

Culture Biosciences operates a cloud-enabled bioreactor fermentation platform serving synthetic biology companies — comparable to Bota's biofoundry-as-a-service offering and overlapping customer base in strain engineering.

TypeDirect peer
Description

Amyris operated precision fermentation to produce bio-based ingredients for personal care, flavors and fragrances — a comparable business model to Bota's branded Yucca Elements and HeliaGenesis ingredient businesses (though Amyris's restructuring illustrates execution risk).

TypeBroad incumbent
Description

Novonesis (the merged Novozymes-Christian Hansen) is the world's largest industrial enzyme and microbial platform company — a broad incumbent in the same industrial biotech / precision fermentation space Bota addresses via its enzyme engineering offering.

TypeBroad incumbent
Description

dsm-firmenich is a global ingredients giant spanning food, nutrition, personal care and flavors — overlapping with Bota's Yucca Elements (personal care) and HeliaGenesis (food nutrition) branded ingredient offerings through comparable B2B distribution.

TypeBroad incumbent
Description

IFF is a major global ingredients and biosciences company with significant fermentation and enzyme capabilities (Health & Biosciences division) — a broad incumbent comparable to Bota across flavors, food enzymes, and personal care ingredients.

TypeEmerging player
Description

Pivot Bio uses synthetic biology to engineer microbial nitrogen-fixation for agriculture — fellow WEF Technology Pioneer Unicorn alongside Bota, demonstrating the comparable synthetic-biology-platform-meets-industrial-application archetype.

TypeDirect peer
Description

Codexis is a leading enzyme engineering company using directed evolution and computational protein design to develop industrial biocatalysts — directly comparable to Bota's Rapid Iterative Enzyme Engineering offering and its Puratos/BASF enzyme partnerships.

TypeDirect peer
Description

Ginkgo Bioworks operates the largest commercial biofoundry (Foundry) and provides cell programming and strain engineering services across food, agriculture, and industrial biotech — directly comparable to Bota's Bota Biofoundry platform and SynBio services model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability13 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bota Biosciences

Industrial Synthetic Biology / Bio-manufacturingbota.bio

Bota Biosciences (恩和科技) is a Hangzhou-based synthetic biology and Physical AI company that builds the SAION AI platform and Bota Biofoundry to design, engineer, and industrially produce precision-fermented bio-based ingredients for food, nutrition, personal care, and fine chemicals customers including BASF, Syensqo, NHU, Proya, and Puratos.

What Bota Biosciences does

Bota Biosciences (恩和科技) is an industrial synthetic biology and Physical AI company founded in September 2019 by Dr. Cheryl Cui in Hangzhou, China. The company builds and operates the SAION AI Physical AI platform — a three-layer system integrating Cognition (multi-scale biological understanding via AI4Science models and proprietary Cell2Cloud datasets), Orchestration (an Agent Harness engine coordinating 316 specialized scientific tools), and Closed-loop Execution (BPL-driven automated wet-lab operation). This platform is anchored by the in-house Bota Biofoundry (Cell2Cloud) which has been operational since 2020, screening 1.5M+ strains per year across 48 bioreactors and generating a proprietary dataset of 10M+ multi-modal closed-loop data points and 1.8B+ process data points. Bota also developed and open-sourced the Biology Protocol Language (BPL) and BPL-COGEN compiler pipeline under MIT License, achieving 95.1% first-pass and 98.6% after two rounds of compiler-simulation on 300 Nature Protocols papers.

The company monetizes across three revenue streams: (1) B2B precision fermentation services and joint development with industrial partners (NHU, Puratos, BASF, Syensqo, Proya, Pechoin, Yili) using a land-and-expand model with multi-year strategic alliances; (2) self-developed branded bio-based product sales through two wholly-owned sub-brands — Yucca Elements for personal care (Prorylia® FN, Re² Coffea Arabica Peptide, ZeaVida) and HeliaGenesis for food/nutrition bio-preservatives (Purtect™ Nisin, Natamycin, ε-Poly-Lysine, Lysozyme); and (3) technology transfer, licensing and commercialization royalties. The company holds an integrated industrial footprint of 130,000 m² with 600+ tons/year capacity across Hangzhou (HQ + LEAP R&D Center), Shandong, and Ordos production sites, plus a US regional office in Lafayette, CA.

Bota was recognized as a World Economic Forum Technology Pioneers Unicorn (January 2024), selected for the WEF MINDS program (2026), named to Forbes China's AI Technology Enterprise Top 50 (2026), and designated one of Hangzhou's "New Eight Steeds" (2026). The company achieved FDA GRAS certification for ZeaVida® precision-fermented zeaxanthin in May 2026 — a world-first for cell-factory carotenoid production — and rebranded in March 2026 from 恩和生物 (Enhe Bio) to 恩和科技 (Enhe Technology) to reflect its AI-driven positioning. Disclosed revenue was approximately 100 million RMB by December 2023 (up from >10 million RMB in May 2022); cumulative disclosed funding exceeds US$100M+ across Series A (May 2020), Series B (July 2021) and Series B+ (June 2024), with investors including BASF Venture Capital, Sherpa Healthcare Partners, Matrix Partners China, Baidu Ventures, HSG, 5Y Capital, and Source Code Capital.

Bota Biosciences firmographics

Firmographics
Name
Bota Biosciences
Legal name
Bota Biosciences
Website
https://bota.bio
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Bota Biosciences (恩和科技) is a Hangzhou-based synthetic biology and Physical AI company that builds the SAION AI platform and Bota Biofoundry to design, engineer, and industrially produce precision-fermented bio-based ingredients for food, nutrition, personal care, and fine chemicals customers including BASF, Syensqo, NHU, Proya, and Puratos.
Ownership category
akta.pro rank

Bota Biosciences industry classification

Industry
Product category
Industrial Synthetic Biology / Bio-manufacturing
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYEUAAAIAL
Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYAFABAEAM
Biological Formulation, Fermentation & Scale-Up Manufacturing
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)

Keywords

  • Synthetic biology
  • Precision fermentation
  • Bio-based ingredients
  • Enzyme engineering
  • Biomanufacturing services

Where Bota Biosciences is headquartered

Location

Headquarters

HQ city
Lafayette
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Bota Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Precision fermentation services & joint development: B2B service offering full-stack precision fermentation capabilities — partners bring market insight and target molecules; Bota delivers strain engineering, process development, scale-up, and industrialization. Land-and-expand model with multi-year strategic alliances (e.g., 5-year Syensqo partnership).
  2. Branded bio-based product sales (Yucca Elements / HeliaGenesis): Self-developed and mass-produced high-value bio-based ingredients for personal care (Yucca Elements: Prorylia FN, Re2 Coffea Arabica Peptide, ZeaVida precision-fermented zeaxanthin) and food/nutrition (HeliaGenesis: Purtect Nisin/Natamycin/ε-Poly-Lysine/Lysozyme). Distributed via own e-commerce storefronts and partner commercial networks.
  3. Technology transfer, licensing and commercialization royalties: Out-licensing of proprietary strains, processes and platforms to industrial partners (e.g., NHU strain commercialization delivering multi-million RMB economic value; Puratos enzyme co-development). Includes long-tail royalty potential on commercialized outputs.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Bota Biosciences product offering

Product offering

Core offering

Bota Biosciences operates an AI-driven industrial synthetic biotechnology platform that programs biological systems for precision fermentation and clean bio-manufacturing. Its core commercial offerings are B2B precision-fermentation services (strain engineering, process development, scale-up, industrialization) delivered to Fortune 500 customers, branded bio-based ingredients (bio-preservatives under HeliaGenesis, personal care proteins under Yucca Elements), and technology/strain licensing to industrial partners. The proprietary SAION AI Physical AI Platform and Bota Biofoundry (Cell2Cloud) compress the Design-Build-Test-Learn cycle and link in-silico design directly to industrial-scale fermentation production.

Differentiator

Problem solved

Functional benefit

Brands

  • Yucca Elements (青然新护): Wholly-owned personal care and beauty synthetic biology ingredients sub-brand specializing in pure, natural, high-efficiency bio-based raw materials such as Prorylia® FN Fibronectin and Re² Coffea Arabica peptides.
  • HeliaGenesis (新日元生)

Products and services

  • SAION AI Physical AI Platform End-to-end Physical AI platform that autonomously drives biological design from in-silico cognition through multi-agent orchestration to closed-loop wet-lab execution; offered to biomanufacturing enterprises and used internally to compress R&D-to-industrialization cycles from 3-5 years to as short as 6 months.
  • Bota Biofoundry (Cell2Cloud Biofoundry) In-house full-stack biofoundry platform combining software algorithms, high-throughput data, deep learning, and biotechnology to accelerate Design-Build-Test-Learn cycles for industrial strain engineering, enzyme engineering, and protein discovery; offered to enterprise biomanufacturing customers.
  • Bota Camino

Quantifiable outcome

  • R&D-to-industrialization cycle compressed from 3-5 years to as short as 6 months via SAION AI
  • +6 more outcomes

Companies that use Bota Biosciences

Customer profile

Segments5 records

Ideal customer profiles4 records

Bota Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability13 records

Feature6 records

Bota Biosciences partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

  • BASF, Pechoin (百雀羚), Yili (伊利) and other Fortune 500 / industry leaderscoreStrategic or Co-development Partner · 17 May 2026Disclosed in the Forbes China AI Tech Top 50 announcement as world-500/industry-leading deep partnerships spanning food, nutrition and personal care (also referenced across multiple press releases and on the company's "Proud Partnership with Industry Leaders" homepage section).
  • Proya Co., Ltd. (珀莱雅)coreStrategic or Co-development Partner · 21 May 2025Strategic-level cooperation signing at Proya's Longwu R&D Center in Hangzhou — Proya's first strategic collaboration with a synthetic biology company. Focused on integrated application of synthetic biology and AI in cosmetics and biomedical aesthetics; co-developing AI-designed customized bioactive ingredients.
  • SyensqoflagshipStrategic or Co-development Partner · 10 February 2025Five-year strategic partnership combining Bota's Performance Protein Platform with Syensqo's 40+ years of hair/scalp care expertise, supported by Syensqo's Renewable Materials and Biotechnology Platform and Syensqo Ventures. Expanded in March 2026 to globally distribute Re2 Coffea Arabica Peptide via Syensqo's commercial network.
  • PuratoscoreStrategic or Co-development Partner · 14 July 2024Joint collaboration to expand Puratos' natural enzyme portfolio for bakery, patisserie and chocolate using Bota's extensive enzyme sequence/structure database and Biofoundry platform. Bota identifies and engineers the natural enzymes; Puratos develops and applies them at commercial scale.
  • Zhejiang NHU Co., Ltd. (新和成)coreStrategic or Co-development Partner · 23 June 2024Strategic partnership leveraging NHU's specialty chemical production experience with Bota's full-stack strain development platform. First co-developed project successfully commercialized, generating tens of millions RMB in economic benefits with projected several hundred million RMB in total product value.
  • World Economic Forum (WEF) — Unicorn community membershipflagshipOthers · 31 January 2024Selected to the WEF Unicorns list (alongside OpenAI, Pivot Bio, Asimov) and invited to speak on the 'Bio-based Path to Net Zero' panel at Davos 2024 — a non-commercial recognition of Bota's leadership, impact, and innovation in industrial biotechnology.
  • Agilent TechnologiescoreTechnology or Integration · 7 September 2023Deepened strategic cooperation building on a relationship since 2019. Bota's analytical platform is equipped with Agilent UHPLC, GC, LC-MS/MS, GC-MS and RapidFire high-throughput LC-MS systems; both parties will share technology and industrial resources to optimize metabolic flow analysis, protein quantification, and fermentation online detection for synthetic biology applications.
  • GalacticminorStrategic or Co-development PartnerListed as a proud industry-leader partner on Bota's homepage (Galactic is a lactic acid / natural preservatives specialist), suggesting a supply, development or distribution relationship in the bio-preservative value chain.
  • Siveele (力诚)minorStrategic or Co-development PartnerListed as a proud industry-leader partner on Bota's homepage — partnership in the personal care / consumer products value chain.
  • Wahaha (娃哈哈), Yurun (雨润), Jinluo (金锣), Beter and other Chinese food brandsminorChannel Partner/ Reseller/ DistributorDisclosed on Bota's Chinese homepage as partner customers for food/nutrition ingredients (bio-preservatives and functional ingredients). Customer-type relationships rather than equity alliances.

Scale indicators13 records

Recent moves9 records

Expansion highlights8 records

Bota Biosciences competitors and assessment

Company assessment

Direct peers

  • Conagen: Conagen is a precision fermentation company developing bio-based ingredients for food, flavor, fragrance, and personal care — a direct competitor to Bota in fermentation-based bio-preservatives and performance proteins for personal care.
  • Amyris: Amyris operated precision fermentation to produce bio-based ingredients for personal care, flavors and fragrances — a comparable business model to Bota's branded Yucca Elements and HeliaGenesis ingredient businesses (though Amyris's restructuring illustrates execution risk).
  • Codexis: Codexis is a leading enzyme engineering company using directed evolution and computational protein design to develop industrial biocatalysts — directly comparable to Bota's Rapid Iterative Enzyme Engineering offering and its Puratos/BASF enzyme partnerships.
  • Ginkgo Bioworks: Ginkgo Bioworks operates the largest commercial biofoundry (Foundry) and provides cell programming and strain engineering services across food, agriculture, and industrial biotech — directly comparable to Bota's Bota Biofoundry platform and SynBio services model.

Broad incumbents

  • Corbion: Corbion is a global leader in lactic acid, bio-preservatives (similar to Bota's Nisin/Natamycin/ε-Poly-Lysine portfolio), and natural food ingredients — a directly overlapping product portfolio in bio-preservation.
  • Novonesis (Novozymes): Novonesis (the merged Novozymes-Christian Hansen) is the world's largest industrial enzyme and microbial platform company — a broad incumbent in the same industrial biotech / precision fermentation space Bota addresses via its enzyme engineering offering.
  • dsm-firmenich: dsm-firmenich is a global ingredients giant spanning food, nutrition, personal care and flavors — overlapping with Bota's Yucca Elements (personal care) and HeliaGenesis (food nutrition) branded ingredient offerings through comparable B2B distribution.
  • IFF (International Flavors & Fragrances): IFF is a major global ingredients and biosciences company with significant fermentation and enzyme capabilities (Health & Biosciences division) — a broad incumbent comparable to Bota across flavors, food enzymes, and personal care ingredients.

Emerging players

  • Culture Biosciences: Culture Biosciences operates a cloud-enabled bioreactor fermentation platform serving synthetic biology companies — comparable to Bota's biofoundry-as-a-service offering and overlapping customer base in strain engineering.
  • Pivot Bio: Pivot Bio uses synthetic biology to engineer microbial nitrogen-fixation for agriculture — fellow WEF Technology Pioneer Unicorn alongside Bota, demonstrating the comparable synthetic-biology-platform-meets-industrial-application archetype.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

Bota Biosciences social profiles

Digital presence

Bota Biosciences compliance and trust

Trust signal

Compliance2 records

Bota Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bota Biosciences leadership team

Management profile

Number of profiles

Profiles9 records

Bota Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Bota Biosciences funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bota Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bota Biosciences

What does Bota Biosciences do?

Bota Biosciences operates an AI-driven industrial synthetic biotechnology platform that programs biological systems for precision fermentation and clean bio-manufacturing. Its core commercial offerings are B2B precision-fermentation services (strain engineering, process development, scale-up, industrialization) delivered to Fortune 500 customers, branded bio-based ingredients (bio-preservatives under HeliaGenesis, personal care proteins under Yucca Elements), and technology/strain licensing to industrial partners. The proprietary SAION AI Physical AI Platform and Bota Biofoundry (Cell2Cloud) compress the Design-Build-Test-Learn cycle and link in-silico design directly to industrial-scale fermentation production.

Is Bota Biosciences a public or private company?

Bota Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bota Biosciences founded?

Bota Biosciences was founded in 2019. It employs 11 to 50 people.

Where is Bota Biosciences based?

Bota Biosciences is headquartered in Lafayette, United States, in the North America region.

How does Bota Biosciences make money?

Three revenue lines are on record. Precision fermentation services & joint development is the primary driver. The others are branded bio-based product sales (Yucca Elements / HeliaGenesis) and technology transfer, licensing and commercialization royalties.

Who are Bota Biosciences's main competitors?

Direct peers on record are Conagen, Amyris, Codexis and Ginkgo Bioworks. Broad incumbents are Corbion, Novonesis (Novozymes), dsm-firmenich and IFF (International Flavors & Fragrances). Emerging players are Culture Biosciences and Pivot Bio.

Does Bota Biosciences have an API?

No public API is recorded for Bota Biosciences.

What industry is Bota Biosciences in?

Bota Biosciences's product category is Industrial Synthetic Biology / Bio-manufacturing. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAJAF, Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TrendHunter.comAI Biomanufactured BeautyBASF and Bota Biosciences partnered to develop SkinNexus™ Collag3n, an AI-designed collagen ingredient for skincare, using Bota's Physical AI-driven biofoundry that screened over 2,000 collagen fragments for both biological performance and manufacturing viability. The resulting vegan, human-identical Collagen III fragment is produced through yeast fermentation and is designed to support the skin's natural collagen balance. By integrating digital discovery with scalable biomanufacturing, the collaboration offers personal care companies an approach to develop scientifically validated ingredients with greater production consistency and sustainability than traditional sourcing methods.Third NewsBota Biosciences and BASF Unveil Innovative Bio-Identical Collagen III Influenced by AIBota Biosciences and BASF have jointly launched SkinNexus™ Collag3n, a bio-identical Collagen III ingredient for personal care, at the in-cosmetics Global event in April 2026. The product was developed using AI-driven screening of over 2,000 collagen fragments and demonstrated significant efficacy in laboratory and clinical studies, showing increases in collagen production up to +82% and visible skin improvements in women ages 53–70 after four weeks of application. This collaboration marks a milestone in bio-based skincare innovations, combining Bota's AI-driven biomanufacturing capabilities with BASF's cosmetic active technologies.PR NewswireBota Biosciences and BASF Introduce Bio-Identical Collagen III Powered by AIBota Biosciences and BASF jointly announced the market launch of SkinNexus™ Collag3n, a 100% human-identical recombinant Collagen III fragment for the personal care market, developed using Bota's Physical AI-driven biofoundry capabilities combined with BASF's cosmetic actives technology, with over 2,000 collagen fragments screened during development. Clinical trials on women aged 53–70 demonstrated improvements in sagging and wrinkle appearance after four weeks, outperforming a collagen benchmark used at ten times the concentration. This launch marks a milestone in the ongoing collaboration between the two companies in bio-based innovations for the global market.PR Newswire APACBota Biosciences and BASF Introduce Bio-Identical Collagen III Powered by AIBota Biosciences and BASF jointly announced the market launch of SkinNexus™ Collag3n, a 100% human-identical recombinant Collagen III fragment for the personal care market, developed using AI-driven biofoundry capabilities and screened from over 2,000 collagen fragments. The ingredient, which debuted at in-cosmetics Global in April 2026, demonstrated in clinical trials on women aged 53–70 that it improved sagging and wrinkle appearance after four weeks, outperforming a collagen benchmark used at ten times the concentration. This launch marks an important milestone in the ongoing collaboration between the two companies in bio-based innovations for the global market.Third NewsBota Biosciences Unveils Groundbreaking Biology Protocol Language for Enhanced AI BiomanufacturingBota Biosciences announced the launch of its Biology Protocol Language (BPL) and accompanying BPL-COGEN generation pipeline designed to standardize biological protocols through machine verification, addressing reproducibility challenges that affect over 70% of researchers according to a 2016 survey. The system achieved 95.1% first-pass consistency on 300 published protocols, improving to 98.6% after two rounds of compiler-simulation, and operates as the execution layer for Bota's SAION AI biofoundry platform. The company positioned this launch against a projected $6 trillion biomanufacturing market by 2035, positioning formal protocol standards as foundational to the industry's future similar to how compiler infrastructure became essential for semiconductors and software.PR NewswireBota Biosciences Releases BPL, a Compiler-Verified Protocol Language for AI-Driven BiomanufacturingBota Biosciences released the Biology Protocol Language (BPL) and its generation pipeline BPL-COGEN, a compiler-verified protocol language designed to address reproducibility failures in biological research by formally verifying experimental protocols before execution. Tested against 300 published Nature Protocols papers, the system achieved 95.1% first-pass consistency, improving to 98.6% after two rounds of compiler-simulation feedback, and was simultaneously selected for the World Economic Forum's MINDS program 2026. BPL serves as the execution layer of Bota's Physical AI-driven biofoundry platform SAION AI, positioning formal protocol standards as foundational infrastructure for a biomanufacturing market projected to reach $6 trillion by 2035.LeiphoneFrom code to production line: Enhe releases BPL protocol language, defining the 'industrial-grade compiler' for biomanufacturing.Enhe released BPL, a formal language for biological protocols, and BPL-COGEN, a compiler that translates natural-language SOPs into BPL. On 300 Nature Protocols papers, BPL-COGEN achieved 95.1% initial consistency and 98.6% after two compilation-simulation rounds. The code is open-sourced under MIT License.BusinessLineHangzhou Investment Promotion Bureau: Meet Hangzhou’s New Eight Steeds that will define the next decadeIn May 2026, Hangzhou hosted an investment promotion conference where eight cutting-edge tech startups were dubbed the "New Eight Steeds" by local media, focusing on frontier tracks such as smart glasses, chip manufacturing, space-based computing, embodied AI, and biomanufacturing. The eight companies—Hangzhou Lingban Technology, Star.Vision, Hangzhou Jinglianwen Technology, Xynova, Sunrise, Nanocorechip, BIBO, and Bota Biosciences—represent a shift from the earlier "Six Little Dragons" that focused on internet applications toward hard-tech and industrial foundations. Capital enthusiasm is high, with local state-owned funds and industrial capital from Beijing, Shanghai, and Shenzhen supporting these companies, while external investors like Xiaomi, Lenovo, and ByteDance are also investing.PR NewswireHangzhou Investment Promotion Bureau: Meet Hangzhou's New Eight Steeds that will define the next decadeIn May 2026, Hangzhou hosted an investment promotion conference where eight cutting-edge tech startups were unveiled as the city's "New Eight Steeds," focusing on frontier technologies including smart glasses, chip manufacturing, space-based computing, embodied AI, and biomanufacturing. These eight companies—Hangzhou Lingban Technology, Star.Vision, Hangzhou Jinglianwen Technology, Xynova, Sunrise, Nanocorechip, BIBO, and Bota Biosciences—represent a strategic shift from internet applications toward hard-tech industrial foundations. Capital interest is noted from local state-owned funds and external investors including Xiaomi, Lenovo, and ByteDance, with the Hangzhou Investment Promotion Bureau organizing the initiative to position the city as an internally driven innovation powerhouse over the next decade.Premium Beauty NewsSyensqo leverages its partnership with Bota BiosciencesSyensqo unveiled Re2 Coffea Arabica Peptide, a bio-based active from recycled coffee grounds, at in-cosmetic Global 2026. The ingredient, designed by Bota Biosciences' AI, offers hydration, soothing, and anti-inflammatory benefits. It also introduced new skin and hair care solutions.